N-ethyl-N'-(3-{[4-(3-isopropyl-2,4-dioxo-1,3,7-triazaspiro[4.5]dec-7-yl)piperidin-1-yl]carbonyl}-6-methylthieno[2,3-b]pyridin-2-yl)urea | 1042441-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N-ethyl-N'-(3-{[4-(3-isopropyl-2,4-dioxo-1,3,7-triazaspiro[4.5]dec-7-yl)piperidin-1-yl]carbonyl}-6-methylthieno[2,3-b]pyridin-2-yl)urea
• 英文别名: 1-[3-[4-(2,4-Dioxo-3-propan-2-yl-1,3,9-triazaspiro[4.5]decan-9-yl)piperidine-1-carbonyl]-6-methylthieno[2,3-b]pyridin-2-yl]-3-ethylurea
• CAS: 1042441-04-2
• 化学式: C₂₇H₃₇N₇O₄S
• 分子量: 555.701
• InChiKey: AKUXSTUUYYHYFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  155
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (1,1-二氧代-3-氧代-1,2-苯并噻唑-2(3H)-基)乙酸 在 吡啶 、 正丁基锂 、 亚硝酸特丁酯 、 叠氮磷酸二苯酯 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 、 copper(I) bromide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 18.5h， 生成 N-ethyl-N'-(3-{[4-(3-isopropyl-2,4-dioxo-1,3,7-triazaspiro[4.5]dec-7-yl)piperidin-1-yl]carbonyl}-6-methylthieno[2,3-b]pyridin-2-yl)urea
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.047

文献信息

• SPIRO-RING COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2128163A1

  公开（公告）日：2009-12-02

  The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

  本发明旨在提供一种具有乙酰辅酶A羧化酶（ACC）抑制作用的化合物，该化合物对于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症、癌症等具有卓越疗效。 本发明提供一种由以下式（I）表示的化合物： 其中 R1是氢原子或取代基； 环P是可选择取代的含氮芳香杂环； 环Q是可选择进一步取代的5-至7-成员的含氮非芳香杂环；和 环R是可选择融合的5-至7-成员的非芳香环，进一步可选择取代， 或其盐。
• Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors
  作者：Makoto Kamata、Tohru Yamashita、Asato Kina、Masaaki Funata、Atsushi Mizukami、Masako Sasaki、Akiyoshi Tani、Miyuki Funami、Nobuyuki Amano、Kohji Fukatsu

  DOI：10.1016/j.bmcl.2012.04.047

  日期：2012.6

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.